Your new experience awaits. Try the new design now and help us make it even better

CORRECTION article

Front. Public Health, 17 November 2025

Sec. Substance Use Disorders and Behavioral Addictions

Volume 13 - 2025 | https://doi.org/10.3389/fpubh.2025.1737084

Correction: Targeting pro-dopaminergic agonism to attenuate depression in patients displaying genetic/epigenetic predisposition to hypodopaminergia

This article is a correction to:

  1. Targeting pro-dopaminergic agonism to attenuate depression in patients displaying genetic/epigenetic predisposition to hypodopaminergia

    1. Read original article
Kai-Uwe Lewandrowski,,,, Kai-Uwe Lewandrowski1,2,3,4,5*Kenneth Blum,,,,,,, Kenneth Blum1,6,7,8,9,10,11,12*Alexander P. L. LewandrowskiAlexander P. L. Lewandrowski13Panayotis K. Thanos,Panayotis K. Thanos6,14Albert Pinhasov,Albert Pinhasov1,6Alireza Sharafshah,Alireza Sharafshah1,15David Baron,,David Baron1,7,16Mark S. GoldMark S. Gold17Catherine A. Dennen,Catherine A. Dennen1,18Igor Elman,,Igor Elman1,6,19Aballa Bowirrat,Aballa Bowirrat1,6Edward J. Modestino,Edward J. Modestino1,8Foojan Zeine,,Foojan Zeine1,8,20Nicole Jafari,,Nicole Jafari1,8,21Keerthy Sunder,,,Keerthy Sunder1,7,12,22Milan T. Makale,,Milan T. Makale1,8,23John Giordano,,John Giordano1,8,9Marjorie C. Gondre-Lewis,Marjorie C. Gondre-Lewis1,24Marco LindenauMarco Lindenau1Brian S. FuehrleinBrian S. Fuehrlein25Rajendra D. Badgaiyan,,,Rajendra D. Badgaiyan1,8,26,27Chynna Levin,,Chynna Levin1,8,28Sergio Luis SchmidtSergio Luis Schmidt4Rossano Kepler Alvim FiorelliRossano Kepler Alvim Fiorelli4
  • 1Division of Personalized Genomics, The Blum Institute of Neurogenetics & Behavior, Austin, TX, United States
  • 2Department of Orthopedic Surgery, University of Arizona Tucson Campus, Tucson, AZ, United States
  • 3Department of Orthopaedics, Fundación Universitaria Sanitas, Bogotá, Colombia
  • 4Department of Orthopedics, Hospital Universitário Gaffree Guinle Universidade Federal do Estado do Rio de Janeiro, Rio de Janeiro, Brazil
  • 5Division of Personalized Pain Research and Education, Center for Advanced Spine Care of Southern Arizona, Tucson, AZ, United States
  • 6Department of Molecular Biology and Adelson School of Medicine, Ariel University, Ariel, Israel
  • 7Division of Addiction Research & Education, Center for Sports, Exercise, and Mental Health, Western University of Health Sciences, Pomona, CA, United States
  • 8Brain & Behavior Lab, Department of Psychology, Curry College, Milton, MA, United States
  • 9Division of Recovery and Rehabilitation, JC Recovery and Counseling Center, Hollywood, FL, United States
  • 10Faculty of Education and Psychology, Institute of Psychology, Eötvös Loránd University, Budapest, Hungary
  • 11Department of Psychiatry, University of Vermont, Burlington, VT, United States
  • 12Division of Neuromodulation Research, Karma Doctors & Karma TMS, Palm Springs, CA, United States
  • 13Department of Biological Sciences, Dornsife College of Letters, Arts & Sciences, University of Southern California, Los Angeles, CA, United States
  • 14Behavioral Neuropharmacology and Neuroimaging Laboratory on Addictions, Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biosciences, Clinical Research Institute on Addictions, State University of New York at Buffalo, Buffalo, NY, United States
  • 15Cellular and Molecular Research Center, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
  • 16Department of Psychiatry & Behavioral Sciences, Stanford University School of Medicine, Palo Alto, CA, United States
  • 17Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, United States
  • 18Department of Family Medicine, Jefferson Health Northeast, Philadelphia, PA, United States
  • 19Department of Psychiatry, Cambridge Alliance, Harvard University School of Medicine, Cambridge, MA, United States
  • 20Department of Health Science, California State University at Long Beach, Long Beach, CA, United States
  • 21Department of Applied Clinical Psychology, The Chicago School of Professional Psychology, Los Angeles, CA, United States
  • 22Department of Psychiatry, University of California, Riverside, Riverside, CA, United States
  • 23Department of Radiation Medicine and Applied Sciences, University of California, San Diego, La Jolla, CA, United States
  • 24Department of Anatomy, Howard University College of Medicine, Washington, DC, United States
  • 25Department of Psychiatry, Yale University, New Haven, CT, United States
  • 26Department of Psychiatry, School of Medicine, Texas Tech University Health Sciences Center, Midland, TX, United States
  • 27Department of Psychiatry, Mt. Sinai University School of Medicine, New York, NY, United States
  • 28Department of Clinical Psychology, St. John's University, Queens, NY, United States

A Correction on
Targeting pro-dopaminergic agonism to attenuate depression in patients displaying genetic/epigenetic predisposition to hypodopaminergia

by Lewandrowski, K.-U., Blum, K., Lewandrowski, A. P. L., Thanos, P. K., Pinhasov, A., Sharafshah, A., Baron, D., Gold, M. S., Dennen, C. A., Elman, I., Bowirrat, A., Modestino, E. J., Zeine, F., Jafari, N., Sunder, K., Makale, M. T., Giordano, J., Gondre-Lewis, M. C., Lindenau, M., Fuehrlein, B. S., Badgaiyan, R. D., Levin, C., Schmidt, S. L., and Fiorelli, R. K. A. (2025). Front. Public Health 13:1594872. doi: 10.3389/fpubh.2025.1594872

The title of this article was erroneously given as “Targeting pro-dopaminergic agonism to attenuate and depression in patient's displaying genetic/epigenetic predisposition to hypodopaminergia.”

The correct title of the article is “Targeting pro-dopaminergic agonism to attenuate depression in patients displaying genetic/epigenetic predisposition to hypodopaminergia.”

The original version of this article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: dopamine D2 receptor (DRD2), hypodopaminergia, pro-dopaminergic therapy, stress induced anxiety, genetic predisposition, Reward Deficiency Syndrome (RDS), neurotransmitter regulation, addiction and mood disorders

Citation: Lewandrowski K-U, Blum K, Lewandrowski APL, Thanos PK, Pinhasov A, Sharafshah A, Baron D, Gold MS, Dennen CA, Elman I, Bowirrat A, Modestino EJ, Zeine F, Jafari N, Sunder K, Makale MT, Giordano J, Gondre-Lewis MC, Lindenau M, Fuehrlein BS, Badgaiyan RD, Levin C, Schmidt SL and Fiorelli RKA (2025) Correction: Targeting pro-dopaminergic agonism to attenuate depression in patients displaying genetic/epigenetic predisposition to hypodopaminergia. Front. Public Health 13:1737084. doi: 10.3389/fpubh.2025.1737084

Received: 31 October 2025; Accepted: 03 November 2025;
Published: 17 November 2025.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2025 Lewandrowski, Blum, Lewandrowski, Thanos, Pinhasov, Sharafshah, Baron, Gold, Dennen, Elman, Bowirrat, Modestino, Zeine, Jafari, Sunder, Makale, Giordano, Gondre-Lewis, Lindenau, Fuehrlein, Badgaiyan, Levin, Schmidt and Fiorelli. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Kai-Uwe Lewandrowski, YnVzaW5lc3NAdHVjc29uc3BpbmUuY29t; Kenneth Blum, ZHJkMmdlbmVAZ21haWwuY29t

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.